1021949-47-2 Usage
Description
5-[1-(2,3-DiMethylphenyl)ethenyl]iMidazole is a chemical compound that is identified as an impurity in Dexmedetomidine (D229000), which is an α2-Adrenergic agonist. 5-[1-(2,3-DiMethylphenyl)ethenyl]iMidazole is characterized by its structural features, including a diMethylphenyl group and an ethenyl group attached to the imidazole ring. Its presence as an impurity in Dexmedetomidine suggests that it may have related pharmacological properties or be involved in the synthesis process of the parent compound.
Uses
Used in Pharmaceutical Industry:
5-[1-(2,3-DiMethylphenyl)ethenyl]iMidazole is used as an impurity in the production of Dexmedetomidine, an α2-Adrenergic agonist. Its presence is significant for the pharmaceutical industry as it may affect the quality, efficacy, and safety of the final drug product. Understanding and controlling the levels of this impurity are crucial for ensuring the therapeutic benefits and minimizing potential side effects of Dexmedetomidine.
Used in Research and Development:
As an impurity in Dexmedetomidine, 5-[1-(2,3-DiMethylphenyl)ethenyl]iMidazole may be used in research and development to study its potential effects on the pharmacological properties of the parent compound. This could involve investigating its interactions with the α2-Adrenergic receptors, its role in the sedative and analgesic effects of Dexmedetomidine, and its potential impact on the drug's overall safety profile.
Used in Quality Control and Regulatory Compliance:
The presence of 5-[1-(2,3-DiMethylphenyl)ethenyl]iMidazole as an impurity in Dexmedetomidine necessitates its inclusion in quality control processes and regulatory compliance efforts. This involves developing and validating analytical methods to accurately quantify the levels of this impurity in the final drug product, as well as establishing acceptable limits to ensure the safety and efficacy of the medication.
Used in Drug Synthesis and Process Optimization:
Understanding the role of 5-[1-(2,3-DiMethylphenyl)ethenyl]iMidazole in the synthesis of Dexmedetomidine can help researchers and chemists optimize the manufacturing process. This may involve identifying ways to minimize the formation of this impurity, improving the overall yield and purity of the final product, and reducing the potential for contamination or degradation during production.
Used in Toxicology and Safety Assessment:
As an impurity in a pharmaceutical product, 5-[1-(2,3-DiMethylphenyl)ethenyl]iMidazole may be subject to toxicological and safety assessments. This involves evaluating its potential toxic effects, determining its safety profile, and establishing guidelines for acceptable exposure levels in the final drug product. These assessments are essential for ensuring the overall safety of Dexmedetomidine and protecting patients from potential adverse effects.
Check Digit Verification of cas no
The CAS Registry Mumber 1021949-47-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,1,9,4 and 9 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1021949-47:
(9*1)+(8*0)+(7*2)+(6*1)+(5*9)+(4*4)+(3*9)+(2*4)+(1*7)=132
132 % 10 = 2
So 1021949-47-2 is a valid CAS Registry Number.
InChI:InChI=1S/C13H14N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8H,3H2,1-2H3,(H,14,15)
1021949-47-2Relevant articles and documents
METHOD FOR PREPARING DEXMEDETOMIDINE
-
Page/Page column 19; 21-22, (2021/05/15)
The present invention relates to a method for preparing dexmedetomidine having the following formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, comprising the following successive steps: a) asymmetric hydrogenation of a methylene derivative of the following formula (II): in order to obtain dexmedetomidine, and b) optionally salifying and/or solvating dexmedetomidine in order to obtain a pharmaceutically acceptable salt and/or solvate of dexmedetomidine, wherein the methylene derivative of formula (II) is prepared from a halide of the following formula (V), in which Hal2 represents a halogen atom such as Br, and a cyanoimidazole of the following formula (VI):. The present invention relates also to methods for preparing synthesis intermediates of dexmedetomidine from the halide of formula (V) and the cyanoimidazole of formula (VI), these synthesis intermediates being the methylene derivative of formula (II), an alcohol of the following formula (III), and a ketone of the following formula (IV):.
Preparation method of dexmedetomidine hydrochloride and its intermediate
-
, (2018/07/15)
The invention discloses a preparation method of dexmedetomidine hydrochloride and its intermediate. A preparation method of dexmedetomidine L-tartrate comprises the steps of subjecting dexmedetomidineintermediate III and hydrogen to reduction reaction in an organic solvent in the presence of a chiral catalyst, and subjecting the reduced product and tartaric acid to neutralization reaction to obtain dexmedetomidine L-tartrate II, wherein the chiral catalyst is (+)-1,2-bis(2S-5S)-diethylphospholano-benzene(1,5-cyclooctadiene)rhodium trifluoromethanesulfonate. The preparation method herein has ashort step path, has no need for chiral splitting, and has high total molar yield; the product prepared herein has high purity, reaches the standard for bulk pharmaceutical chemicals and is suitablefor industrial production.
A novel and facile route for the synthesis of medetomidine as the α2-adrenoceptor agonist
Kaboudin, Babak,Haghighat, Hamideh,Aieni, Samira,Behrouzi, Leila,Kazemi, Foad,Kato, Jun-ya,Aoyama, Hiroshi,Yokomatsu, Tsutomu
, p. 1735 - 1739 (2017/06/27)
Abstract: We report here a novel and facile method for the synthesis of (±)-4(5)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole (medetomidine) in a good yield in five steps. The method involves Wittig olefination of the phenylimidazolylketones, followed by a hydrogenation. We demonstrate that the Wittig alkenylation reaction provides a convenient step for the synthesis of medetomidine without requiring methylation and dehydration steps, which are problematic processes in the previous methods. Graphical Abstract: Novel route for the synthesis of medetomidine.[Figure not available: see fulltext.].